Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

· Issued by Ionis Pharmaceuticals, Inc. via PR Newswire
Watch Ionis Pharmaceuticals explain itIonis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call · Replay · Jul 29
  • ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia
  • ION449 will not advance into Phase 3 development based on pre-specified criteria

CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered monthly achieved a statistically significant 62.3% (p